Non Small Cell Lung CancerPhase 1NCT04622072
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 1 study testing XZP-5809-TT1 Tablet in people with Non Small Cell Lung Cancer, run by Sihuan Pharmaceutical Holdings Group Ltd. at 5 sites in China.
Trial summary
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer
- What is being tested?
- XZP-5809-TT1 Tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 5 sitesChina
- Study dates
- 2 Nov 2020to 27 Apr 2022
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with locally advanced or metastatic NSCLC who are diagnosed by histology or cytology and are not suitable for surgery or radiotherapy;
- Patients with EGFR sensitive mutations (including deletion of exon 19, L858R mutation of exon 21, at least one of the above mutations) And after the last treatment (regardless of TKI or chemotherapy), the tissue/cytology specimens collected have been passed through a tertiary A hospital or confirmed as T790M+ by the central laboratory;
- The patient's disease progression after the first or/and second-generation EGFR-TKIs treatment (with imaging or pathological evidence, judged by the research center);
- Life expectancy is not less than 12 weeks, ECOG(Eastern Cooperative Oncology Group, ECOG score) is as follows:
- ECOG score in the dose-escalation phase: 0~1 points, and no deterioration within 2 weeks before enrollment, ECOG score during dose expansion stage: 0~2 points, and no deterioration within 2 weeks before enrollment;
- According to RECIST 1.1, the patient has at least one imaging (CT/MRI) measurable lesion. When the patient has at least one baseline Tumor lesions meet the following requirements: accurate measurement at baseline, non-lymph node lesions with longest diameter ≥10 mm, or short diameter ≥15 mm Of lymph node lesions. Have not received local treatments such as radiotherapy in the past, and have not been used for research screening biopsy (if there is only one Measurable lesions, biopsy of the lesions is allowed, but the lesions must be performed at least 14 days after the screening biopsy Baseline imaging examination), the measurement method is computed tomography [CT] or magnetic resonance imaging [MRI]);
Show all 10Show fewer
- The organ function level must meet the following requirements (no blood transfusion or blood products, no use of hematopoietic stimulating factors, No albumin or blood products are used): absolute neutrophil count (ANC) ≥1.5×109/L, platelet count (PLT)
- ≥75×109/L, hemoglobin (Hb) ≥90 g/L; serum total bilirubin ≤1.5 times the upper limit of normal, aspartate aminotransferase (AST) And alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal value (if there is liver metastasis, total bilirubin ≤3 times the upper limit of normal value is allowed, AST, ALT≤5 times the upper limit of normal); Creatinine clearance (Ccr) ≥50 ml/min (according to Cockcroft and Gault formula); Note: If the researcher thinks it is necessary to retest (the reason for the retest must be recorded), the above laboratory examination can only be retested once. complex After the test meets the standard, then the laboratory parameters can be considered qualified.
- Premenopausal women who are likely to have children must have a pregnancy test within 7 days before starting treatment, and the pregnancy test must be negative Sex, must be non-lactating period; infertile women can not take pregnancy test and contraception, but must meet: age 50 Over the age of, not using hormone therapy and menopause for at least 12 months, or have been sterilized. All enrolled patients (regardless of male (Sexual or female) should take adequate barrier contraceptive measures during the entire treatment period and 3 months after the end of treatment;
- Volunteer to join the group and sign the informed consent, follow the trial treatment plan and visit plan.
Who cannot join
- Have received any of the following treatments in the past:
- First medication (first medication refers to the first use of the test drug, hereinafter referred to as the first medication) patient use within 6 weeks Have used nitrosoureas or mitomycin C, or have used other cytotoxic chemotherapeutics or their drugs within 3 weeks before the first administration His anti-cancer drugs;
- The time from receiving any EGRF-TKI treatment to the first dose does not exceed the 5 half-life of the drug (for example, Elotinib is not more than 8 days, gefitinib is not more than 10 days, icotinib is not more than 2 days, and afatinib is not more than 8 days day);
- The time from receiving other experimental drugs or analogues to the first dose does not exceed the drug's 5 half-life or 14 days (whichever Senior citizens);
- The time from receiving other immune preparations to the first administration does not exceed 28 days;
- Major surgery (excluding vascular access establishment surgery and biopsy surgery) within 4 weeks before the first medication;
Show all 25Show fewer
- The patient has received more than 30% bone marrow radiotherapy or large-area irradiation (excluding bone transfer) within 4 weeks before the first medication.
- Have used third-generation EGFR-TKI drugs, including but not limited to osimertinib mesylate (Teresa®), Rociletinib (CO-1686), Olmutinib (Olita®, HM61713), ASP8273, EGF816, Ametidine mesylate Ni, Iflutinib mesylate (AST2818), Maihuatinib, Ivitinib, etc. or the raw materials and generic drugs of these drugs;
- CYP3A4 strong inhibitors or strong inducers have been used within 7 days before the first administration; CYP3A4 strong inhibitors or strong inducers have been used within 14 days before the first administration Anti-tumor medicines and Chinese medicine preparations, Chinese medicines and Chinese medicine preparations with tumor adjuvant treatment effects, and exclusion criteria Standard 1) Other drugs with anti-tumor activity not mentioned;
- At the beginning of the first medication, there are still unhealed toxic reactions in the previous treatment, and "General Terminology Standards for Adverse Events (CTCAE 5.0)" If the grade exceeds grade 1 (except for hair loss), neuropathy related to previous platinum therapy can be relaxed to grade 2.
- Spinal cord compression or brain metastasis, but the following conditions are allowed to be selected: asymptomatic, stable disease, no need to use before the start of research treatment Patients who have been treated with steroids for 4 weeks (if the brain metastases have received radiotherapy or/and surgery, the radiotherapy and surgery must be separated from the first use1 month and above before medication);
- There are any clinical evidences that suggest severe or uncontrolled systemic diseases, for example, the researcher believes that the patient is not suitable for participation or those that will affect patients' compliance with the research protocol, such as patients with uncontrolled hypertension, patients with uncontrolled diabetes, patients with coronary artery stenosis, patients with aortic dissection, patients with aortic aneurysms, patients with active bleeding Individuals who are on anti-infection treatment;
- Currently existing hepatitis B (hepatitis B surface antigen [HbsAg] positive or core antibody [HbcAb] positive and HBV (hepatitis B virus DNA) positive), hepatitis C (HCV antibody positive and HCV RNA positive), human immunodeficiency virus (HIV) infection;
- Any clinically serious gastrointestinal dysfunction that may affect the intake, transport or absorption of the study drug, such as inability to take it orally Drugs, uncontrollable nausea and vomiting, history of extensive gastrointestinal resection, uncured recurrent diarrhea, atrophic gastritis (with The age of the disease is less than 60 years old), and the proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, Rabeprazole, etc.) of stomach diseases, Crohn's disease, ulcerative colitis;
- Meet any of the following cardiac examination or disease standards:
- In the resting state, the average corrected QT interval (QTc) obtained from ECG examination, QTc interval>470 msec (QTcF=QT/RR1/3, when an abnormality is found in the first inspection, repeat the test twice within 48 hours, with an average of 3 times result calculation);
- Various abnormalities of heart rhythm, conduction, and resting ECG with serious clinical significance, such as complete left bundle branch block,
- Ⅲ degree conduction block, Ⅱ degree conduction block, PR interval>250 msec;
- Various factors that may increase the risk of QTc prolongation or the risk of arrhythmia events, such as heart failure, hypokalemia, Congenital long QT syndrome, first-degree relatives in family history have long QT syndrome or sudden death of unknown cause under 40 years old, Are using any drugs known to extend the QT interval;
- Left ventricular ejection fraction (LVEF) <50%;
- Have the following past history: interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy;
- Acute onset or progressive, and the investigator believes that there are lung symptoms that are not suitable for enrollment or judged that interstitial Patients with high risk factors who are not suitable for entry into the group due to lung disease;
- Any serious or uncontrolled eye pathology, as judged by the investigator, may increase the safety risk of the patient, such as corneal ulcers, Bulbar conjunctivitis, etc.;
- The investigator determines that the patients are not suitable for participating in the study for other reasons (such as: the patient is unwilling to comply with the various procedures and limitations of the study). Regulations and requirements; those who have undergone allogeneic bone marrow transplantation; those who have other malignant tumors in the past 5 years or at the same time [excluding cervical cancer Cancer and treated basal cell carcinoma]; the patient's response to the active ingredients or inactive excipients of the test drug, chemical structure and research drug, medical history of hypersensitivity to similar drugs or similar drugs, etc.);
- At any time after the initial diagnosis, there is a confirmed EGFR 20 exon insertion mutation.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
China5 sites
Cancer hospital Chinese academy of medical sciences
Beijing, Beijing Municipality, 100021
Beijing cancer hospital
Beijing, Beijing Municipality, 100142
Hunan cancer hospital
Changsha, Hunan, 410013
Henan university of science and technology first hospital
Luoyang, Henan, 471003
Henan cancer hospital
Zhengzhou, Henan, 450003
About this study
Official title: A Single-arm, Open, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Effectiveness of XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase.
For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer, and to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
For dose expansion phase, the main purpose is to evaluate Objective response rate (ORR) in patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
- Conditions
- Non Small Cell Lung Cancer
- Being tested
- XZP-5809-TT1 Tablet
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
XZP-5809-TT1 TabletDrug
Single tartrate of XZP-5809
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | For dose escalation phase, subjects are enrolled for different doses of the experimental drug. Receives: Drug: XZP-5809-TT1 Tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
adverse event
Refers to adverse clinical events that occur during drug treatment, which may not have a causal relationship with the drug
Measured: through study completion, an average of 1.5 year
Objective response rate (ORR)
According to the RECIST 1.1 standard, the best overall response (BOR) observed after enrollment of subjects is the proportion of subjects with complete remission (CR) or partial remission (PR)
Measured: through study completion, an average of 1.5 year
Progression-free survival (PFS)
The time from the time a subject receives the first study treatment to the appearance of disease progression or death from any cause (whichever occurs first).
Measured: through study completion, an average of 1.5 year
blood routine
the amount of red blood cell.
Measured: through study completion, an average of 1.5 year
blood routine
the amount of white cell.
Measured: through study completion, an average of 1.5 year
blood routine
the amount of platelet.
Measured: through study completion, an average of 1.5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2020
- Study start2 Nov 2020
- Primary completion20 May 2021
- Study completion27 Apr 2022
Why it stopped: Strategic considerations
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- yuankai Shi, Principal investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04622072
- Sponsor's protocol ID
- XZP-5809-TT1-1001
- Status last verified
- May 2021
- First submitted
- 13 Oct 2020
- Last updated
- 17 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-arm, Open, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Effectiveness of XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
- ClinicalTrials.gov ID
- NCT04622072
- Acronym / sponsor ID
- XZP-5809-TT1-1001
- Conditions
- Non Small Cell Lung Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Strategic considerations
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry (pharma, biotech, devices)
- Study start
- 2 Nov 2020 (actual)
- Primary completion
- 20 May 2021 (actual)
- Study completion
- 27 Apr 2022 (actual)
- First posted
- 9 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase.
For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer, and to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
For dose expansion phase, the main purpose is to evaluate Objective response rate (ORR) in patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Drug: XZP-5809-TT1 TabletFor dose escalation phase, subjects are enrolled for different doses of the experimental drug. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Patients with locally advanced or metastatic NSCLC who are diagnosed by histology or cytology and are not suitable for surgery or radiotherapy;
- Patients with EGFR sensitive mutations (including deletion of exon 19, L858R mutation of exon 21, at least one of the above mutations) And after the last treatment (regardless of TKI or chemotherapy), the tissue/cytology specimens collected have been passed through a tertiary A hospital or confirmed as T790M+ by the central laboratory;
- The patient's disease progression after the first or/and second-generation EGFR-TKIs treatment (with imaging or pathological evidence, judged by the research center);
- Life expectancy is not less than 12 weeks, ECOG(Eastern Cooperative Oncology Group, ECOG score) is as follows:
- ECOG score in the dose-escalation phase: 0~1 points, and no deterioration within 2 weeks before enrollment, ECOG score during dose expansion stage: 0~2 points, and no deterioration within 2 weeks before enrollment;
Key exclusion criteria (25 listed)
- Have received any of the following treatments in the past:
- Have used third-generation EGFR-TKI drugs, including but not limited to osimertinib mesylate (Teresa®), Rociletinib (CO-1686), Olmutinib (Olita®, HM61713), ASP8273, EGF816, Ametidine mesylate Ni, Iflutinib mesylate (AST2818), Maihuatinib, Ivitinib, etc. or the raw materials and generic drugs of these drugs;
- CYP3A4 strong inhibitors or strong inducers have been used within 7 days before the first administration; CYP3A4 strong inhibitors or strong inducers have been used within 14 days before the first administration Anti-tumor medicines and Chinese medicine preparations, Chinese medicines and Chinese medicine preparations with tumor adjuvant treatment effects, and exclusion criteria Standard 1) Other drugs with anti-tumor activity not mentioned;
- At the beginning of the first medication, there are still unhealed toxic reactions in the previous treatment, and "General Terminology Standards for Adverse Events (CTCAE 5.0)" If the grade exceeds grade 1 (except for hair loss), neuropathy related to previous platinum therapy can be relaxed to grade 2.
- Spinal cord compression or brain metastasis, but the following conditions are allowed to be selected: asymptomatic, stable disease, no need to use before the start of research treatment Patients who have been treated with steroids for 4 weeks (if the brain metastases have received radiotherapy or/and surgery, the radiotherapy and surgery must be separated from the first use1 month and above before medication);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| XZP-5809-TT1 TabletSingle tartrate of XZP-5809 | Drug | Experimental group |
Primary outcome
adverse event
Time frame: through study completion, an average of 1.5 year
Refers to adverse clinical events that occur during drug treatment, which may not have a causal relationship with the drug
Objective response rate (ORR)
Time frame: through study completion, an average of 1.5 year
According to the RECIST 1.1 standard, the best overall response (BOR) observed after enrollment of subjects is the proportion of subjects with complete remission (CR) or partial remission (PR)
Progression-free survival (PFS)
Time frame: through study completion, an average of 1.5 year
The time from the time a subject receives the first study treatment to the appearance of disease progression or death from any cause (whichever occurs first).
blood routine
Time frame: through study completion, an average of 1.5 year
the amount of red blood cell.
blood routine
Time frame: through study completion, an average of 1.5 year
the amount of white cell.
blood routine
Time frame: through study completion, an average of 1.5 year
the amount of platelet.
Results and safety
The study was stopped early (reason given: Strategic considerations). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
yuankai Shi principal investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing XZP-5809-TT1 Tablet in people with Non Small Cell Lung Cancer, run by Sihuan Pharmaceutical Holdings Group Ltd. at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 17 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Strategic considerations). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
adverse event (time frame: through study completion, an average of 1.5 year). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2023.